These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
211 related items for PubMed ID: 12028821
21. Presence of crystalline inclusions in the peripheral nerve of a patient with IgA lambda monoclonal gammopathy of undetermined significance. Vital A, Nedelec-Ciceri C, Vital C. Neuropathology; 2008 Oct; 28(5):526-31. PubMed ID: 18410274 [Abstract] [Full Text] [Related]
22. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgM-MGUS neuropathies are different than IgG-MGUS. Suarez GA, Kelly JJ. Neurology; 1993 Jul; 43(7):1304-8. PubMed ID: 8327128 [Abstract] [Full Text] [Related]
23. [Acquired peripheral neuropathies associated with monoclonal gammopathy]. Gajos A, Kieliś W, Szadkowska I, Chmielowska E, Niewodniczy A, Bogucki A. Neurol Neurochir Pol; 2007 Jul; 41(2):169-75. PubMed ID: 17530580 [Abstract] [Full Text] [Related]
24. Sensitivity and specificity of electrodiagnostic criteria for CIDP using ROC curves: comparison to patients with diabetic and MGUS associated neuropathies. Wilson J, Chawla J, Fisher M. J Neurol Sci; 2005 Apr 15; 231(1-2):19-28. PubMed ID: 15792816 [Abstract] [Full Text] [Related]
25. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, Sørensen HT. Haematologica; 2001 Nov 15; 86(11):1172-9. PubMed ID: 11694403 [Abstract] [Full Text] [Related]
26. [Paraproteinemic neuropathies: foundations for a specific therapy related to patients' quality of life]. Casadevall Codina T, Pérez Lázaro C, Santos S, Fabre Pi O, Garcés Redondo M, Larrodé Pellicer P. Rev Neurol; 2001 Nov 15; 38(7):631-6. PubMed ID: 15098183 [Abstract] [Full Text] [Related]
27. [Experiences in the diagnosis and treatment of polyneuropathies in patients with malignant monoclonal gammopathy]. Baumann I, Krause T, Schwenke H, Lehmann J. Psychiatr Neurol Med Psychol (Leipz); 1990 Feb 15; 42(2):85-95. PubMed ID: 2158116 [Abstract] [Full Text] [Related]
28. Lower bone mineral density in geriatric patients with monoclonal gammopathy of undetermined significance. Dizdar O, Erman M, Cankurtaran M, Halil M, Ulger Z, Yavuz BB, Ariogul S, Pinar A, Harputluoglu H, Kars A, Celik I. Ann Hematol; 2008 Jan 15; 87(1):57-60. PubMed ID: 17874101 [Abstract] [Full Text] [Related]
29. Prevalence of monoclonal gammopathy of undetermined significance. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ. N Engl J Med; 2006 Mar 30; 354(13):1362-9. PubMed ID: 16571879 [Abstract] [Full Text] [Related]
30. [Polyneuropathy associated with monoclonal gammopathy of undetermined significance]. Moth Henriksen M, Kolmos EB, Abildgaard N, Schrøder HD, Sindrup S. Ugeskr Laeger; 2012 Oct 22; 174(43):2630-4. PubMed ID: 23095652 [Abstract] [Full Text] [Related]
31. Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities. Notermans NC, Wokke JH, Lokhorst HM, Franssen H, van der Graaf Y, Jennekens FG. Brain; 1994 Dec 22; 117 ( Pt 6)():1385-93. PubMed ID: 7820574 [Abstract] [Full Text] [Related]
32. Polyneuropathy in nonmalignant IgM plasma cell dyscrasia: a morphological study. Nemni R, Galassi G, Latov N, Sherman WH, Olarte MR, Hays AP. Ann Neurol; 1983 Jul 22; 14(1):43-54. PubMed ID: 6311075 [Abstract] [Full Text] [Related]
33. Diagnostic value of the concentration of M-component in initial classification of monoclonal gammopathy. Møller-Petersen J, Schmidt EB. Scand J Haematol; 1986 Mar 22; 36(3):295-301. PubMed ID: 3704554 [Abstract] [Full Text] [Related]
34. Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. Di Troia A, Carpo M, Meucci N, Pellegrino C, Allaria S, Gemignani F, Marbini A, Mantegazza R, Sciolla R, Manfredini E, Scarlato G, Nobile-Orazio E. J Neurol Sci; 1999 Mar 15; 164(1):64-71. PubMed ID: 10385050 [Abstract] [Full Text] [Related]
35. Small fibre involvement in neuropathy associated with IgG, IgA and IgM monoclonal gammopathy. Barbieri S, Sandroni P, Nobile-Orazio E, Cappellari A, Cavestro C, Baldini L, Scarlato G. Electromyogr Clin Neurophysiol; 1995 Mar 15; 35(1):39-44. PubMed ID: 7737014 [Abstract] [Full Text] [Related]
36. [Study of monoclonal gammopathy in Kagawa Prefectural Central Hospital]. Uchida M, Taida N, Kanao M, Kagamihara H, Kuwajima M. Rinsho Byori; 2004 Jul 15; 52(7):574-9. PubMed ID: 15344556 [Abstract] [Full Text] [Related]
37. [The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma]. Scudla V, Budíková M, Pika T, Bacovský J, Minarík J, Heinzová V, Langová K. Cas Lek Cesk; 2009 Jul 15; 148(7):315-22. PubMed ID: 19642297 [Abstract] [Full Text] [Related]
38. [Rapid development of primary amyloidosis after two years' follow-up of monoclonal gammopathy of undetermined significance (MGUS)]. Kanoh T, Inoue M, Okuma M. Rinsho Ketsueki; 1993 Aug 15; 34(8):952-6. PubMed ID: 8411650 [Abstract] [Full Text] [Related]
39. IgM MGUS associated with anti-MAG neuropathy: a single institution experience. Talamo G, Mir MA, Pandey MK, Sivik JK, Raheja D. Ann Hematol; 2015 Jun 15; 94(6):1011-6. PubMed ID: 25572169 [Abstract] [Full Text] [Related]
40. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Gobbi PG, Baldini L, Broglia C, Goldaniga M, Comelli M, Morel P, Morra E, Cortelazzo S, Bettini R, Merlini G. Clin Cancer Res; 2005 Mar 01; 11(5):1786-90. PubMed ID: 15756000 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]